Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Accounts Payables: 2019-2024

Historic Accounts Payables for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $16.4 million.

  • Silence Therapeutics' Accounts Payables rose 191.64% to $17.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.0 million, marking a year-over-year increase of 191.64%. This contributed to the annual value of $16.4 million for FY2024, which is 5.55% up from last year.
  • Per Silence Therapeutics' latest filing, its Accounts Payables stood at $16.4 million for FY2024, which was up 5.55% from $15.5 million recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Accounts Payables ranged from a high of $16.4 million in FY2024 and a low of $10.5 million during FY2020.
  • Its 3-year average for Accounts Payables is $15.9 million, with a median of $15.6 million in 2022.
  • Its Accounts Payables has fluctuated over the past 5 years, first skyrocketed by 41.03% in 2021, then decreased by 0.62% in 2023.
  • MRY analysis of 5 years shows Silence Therapeutics' Accounts Payables stood at $10.5 million in 2020, then skyrocketed by 41.03% to $14.8 million in 2021, then rose by 5.38% to $15.6 million in 2022, then decreased by 0.62% to $15.5 million in 2023, then increased by 5.55% to $16.4 million in 2024.
  • Its Accounts Payables was $16.4 million in FY2024, compared to $15.5 million in FY2023 and $15.6 million in FY2022.